Needham Maintains Buy on Medtronic, Raises Price Target to $114
Needham analyst Mike Matson maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $101 to $114.
Read original at benzingaStocks · News reference
- Reuters Citing Attorney
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Needham analyst Mike Matson maintains Medtronic (NYSE:MDT) with a Buy and raises the price target from $101 to $114.
Read original at benzingaThe global atrial fibrillation treatment devices market is expected to grow at a 13.1% CAGR from $9.6 billion in 2026 to $29 billion by 2035, driven by aging populations, rising AF prevalence affecting 50-60 million people worldwide, and increasing adoption of advanced ablation and left atrial appendage closure technologies. Pulsed field ablation is forecast to generate over 60% of market revenue by 2035, while North America will retain approximately 50% of global market share. Asia-Pacific is expected to register the fastest regional growth.
Read original at globenewswire-incThe global veterinary medical devices market is projected to grow from $6.5 billion in 2024 to $9.1 billion by 2030 at a 6.1% CAGR, driven by pet humanization trends, expanding pet insurance coverage, and AI-enabled diagnostic innovations. North America dominates with 55.9% market share, while emerging markets present long-term growth opportunities.
Read original at globenewswire-incThe global Intravascular Lithotripsy (IVL) market is projected to grow from USD 1.01 billion in 2025 to USD 4.19 billion by 2035, expanding at a 15.3% CAGR. Growth is driven by increasing prevalence of calcified coronary and peripheral artery disease, adoption of minimally invasive procedures, and expanding peripheral IVL applications. North America leads with 58% market share, while Asia-Pacific is the fastest-growing region.
Read original at globenewswire-inc